Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 11:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,938 matching trials from the live ClinicalTrials.gov search.
Conditions
Neoplasms
Interventions
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
64
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more
Conditions
Ulcerative Colitis
Interventions
OPC-6535, Asacol®
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
26
States / cities
Huntsville, Alabama • Los Angeles, California • Hollywood, Florida + 23 more
Conditions
Metastatic Colorectal Cancer
Interventions
capecitabine and cetuximab
Drug
Lead sponsor
Translational Genomics Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Spokane, Washington
Conditions
Colorectal Cancer
Interventions
ixabepilone, Fluoropyrimidine, Irinotecan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Birmingham, Alabama • Atlanta, Georgia
Conditions
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more
Conditions
Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer
Interventions
Fruquintinib, Tislelizumab
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 12 more
Completed Not applicable Interventional Accepts healthy volunteers

Understanding and Discouraging Overuse of Potentially Harmful Screening Tests

NCT01694784
Conditions
Preventive Screening, Prostate Cancer, Osteoporosis, Colorectal Cancer
Interventions
Quantitative Information Sheet, Qualitative Information Sheet, Narrative Information Sheet, Framed Information Sheet
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 85 Years
Enrollment
775 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Microsatellite Stable Metastatic Colorectal Cancer
Interventions
Evorpacept (ALX148), Cetuximab, Pembrolizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Tucson, Arizona • Aurora, Colorado • New Brunswick, New Jersey + 1 more
Conditions
Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer
Interventions
Vandetanib, Capecitabine, Oxaliplatin, Bevacizumab
Drug
Lead sponsor
Branimir Sikic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Conditions
Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer, Lymphoma, Salivary Gland Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Small Intestine Cancer, Stomach Cancer, Urinary Bladder Cancer, Anal Cancer, Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Kidney Cancer, Penile Cancer, Skin Cancer, Testicular Cancer, Thyroid Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
Interventions
Standard assistance, Enhanced assistance
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Prostate Cancer, Breast Cancer, Colorectal Cancer, Thoracic Cancer
Interventions
CIS (Cancer Information Service) Information Sheet, Facing Forward booklet
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
oxaliplatin, capecitabine, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Conditions
Colon Cancer, Rectal Cancer
Interventions
Surveys
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Interventions
AZD0022, Cetuximab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Duarte, California • New York, New York • Fairfax, Virginia
Completed Not applicable Interventional Accepts healthy volunteers

A Sustainable Approach to Increasing Cancer Screening

NCT01395459
Conditions
Colorectal Cancer, Breast Cancer, Cervical Cancer
Interventions
IVR only, IVR+PCC
Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
21 Years to 86 Years
Enrollment
13,675 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Lawrence, Massachusetts
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, paclitaxel
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Advanced Solid Tumors, Colorectal Cancer
Interventions
VVD-133214, Pembrolizumab, Bevacizumab
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Tucson, Arizona • Duarte, California • Irvine, California + 13 more
Conditions
Solid Tumor
Interventions
PF-07284892, lorlatinib, binimetinib, cetuximab, encorafenib
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more
Conditions
Breast Cancer, Colorectal Cancer
Interventions
Embedded primary care in cancer survivorship model
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
21 Years and older
Enrollment
2,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Anaheim, California • Baldwin Park, California • Downey, California + 9 more
Conditions
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer
Interventions
[68Ga]Ga-NNS309, [177Lu]Lu-NNS309
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 6 more
Conditions
Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
Interventions
enadenotucirev, nivolumab
Biological
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Tucson, Arizona • Duarte, California • Santa Monica, California + 3 more
Conditions
Refractory Metastatic Colorectal Cancer
Interventions
Trifluridine/Tipiracil, Bevacizumab
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Phoenix, Arizona • Duarte, California • South Pasadena, California + 9 more
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study Evaluating the Efficacy of AlloMEM After Loop Ileostomy

NCT01113736
Conditions
Colon Cancer, Rectal Cancer
Interventions
AlloMEM™
Biological
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Colorectal Cancer
Interventions
RAD001, FOLFOX, Bevacizumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Salt Lake City, Utah